MGR001 / Advair Diskus Local Equivalence Study in Asthma

Key inclusion criteria include: * Male or female subjects aged ≥18 years. Females may be of either childbearing or non-childbearing potential * Physician diagnosed history of asthma for at least 12 weeks prior to screening * pre-bronchodilator FEV1 60-85% at screening and other specified visits * Post-bronchodilator reversibility \>/=12% * Non-smokers and prior smokers with no history of smoking within the past 12 months prior to screening and a total smoking history of ≤10 pack-years * Subjects able to discontinue asthma medications for the duration of the study and be maintained using albuterol as required * Body mass index between 18-40 kg/m2 inclusive Key exclusion criteria include: * Presence or recent history of any other active, severe, progressive, and/or uncontrolled clinical disease, eg, poorly controlled Type 1 or 2 diabetes, seizure disorder or epilepsy, cerebrovascular accident, significant cardiac conduction abnormalities * Respiratory conditions other than asthma and allergic rhinitis, including but not limited to: severe nasal polyposis or chronic rhinosinusitis, chronic obstructive pulmonary disease, bronchiectasis, Churg-Strauss Disease, lung resection, pulmonary fibrosis (primary or secondary), pulmonary hypertension, cystic fibrosis, sarcoidosis * History of life-threatening asthma, defined as a history of asthma episode(s) requiring intubation, and/or associated with hypercapnia; respiratory arrest or hypoxic seizures, asthma related syncopal episode(s) * In patient hospitalization (not including ER visits) for an asthma exacerbation within the past year or during the run in period * An asthma exacerbation requiring change in asthma therapy or oral/IV corticosteroids in the 3 months prior to screening * History of seasonally unstable asthma where the season will coincide with the subject's participation in the study * Use of prescription or non-prescription drugs, including beta blockers, tricyclic antidepressants, oral decongestants, benzodiazepines, digitalis, phenothiazines, monoamine oxidase inhibitors, etc * Suspected hypersensitivity to the study drugs (including lactose) or severe milk protein allergy * Clinically significant abnormalities in the screening ECG * Evidence of alcohol or drug abuse or dependency within 6 months prior to screening